Abstract: The invention generally relates to improved processes for the preparation of intermediates of a cyclic dinucleotide which is useful as a STING agonist.

Abstract: A left atrial appendage occlusion device and a delivery system are provided, wherein the left atrial appendage occlusion device includes a stent and an occluder. Firstly, the stent is implanted and fixed at the entrance of the left atrial appendage; then, a double-disc occluder is released on the stent to occlude the left atrial appendage. The left atrial appendage occlusion device includes a self-expandable nitinol stent, which is firmly fixed at the entrance of the left atrial appendage via a two-way anchoring thorn, and then an occluder is released on the stent. The left atrial appendage occlusion device is delivered to the left atrial appendage by the delivery system. Compared with the prior art, the delivery system improves the releasing accuracy and the implanting stability of the occluder. After being released, both the stent and the occluder can be withdrawn into a catheter to be relocated or replaced.

Abstract: A left atrial appendage occlusion device and a delivery system are provided, wherein the left atrial appendage occlusion device includes a stent and an occluder. Firstly, the stent is implanted and fixed at the entrance of the left atrial appendage; then, a double-disc occluder is released on the stent to occlude the left atrial appendage. The left atrial appendage occlusion device includes a self-expandable nitinol stent, which is firmly fixed at the entrance of the left atrial appendage via a two-way anchoring thorn, and then an occluder is released on the stent. The left atrial appendage occlusion device is delivered to the left atrial appendage by the delivery system. Compared with the prior art, the delivery system improves the releasing accuracy and the implanting stability of the occluder. After being released, both the stent and the occluder can be withdrawn into a catheter to be relocated or replaced.

Abstract: A process for producing an enantiomerically enriched compound of Formula I: where the R-configuration, or S-configuration at the stereogenic center is marked with an *; by hydrogenating an enamide of formula III: in an organic solvent in the presence of a catalyst comprising a transition metal selected from rhodium or iridium, complexed to a chiral diphosphine ligand; Ar is optionally substituted phenyl; Z is OR1, SR1 or NR1R2; and P is R3, OR3 or NR3R4; R1 and R2 are selected from H, C1-8 alkyl, C5-12 cycloalkyl, aryl and aryl-C1-2-alkyl; or R1 and R2 together with the nitrogen atom form a C4-7-membered heterocyclic ring optionally fused with a 5- to 6-membered carbocyclic or heterocyclic ring; and R3 and R4 are selected from H, C1-8 alkyl, aryl, C5-12 cycloalkyl and aryl-C1-2-alkyl; or R3 and R4 together with the nitrogen atom form a C4-7-membered heterocyclic ring.

Abstract: A process for producing an enantiomerically enriched, pure or enriched and essentially pure compound of Formula I: wherein the R-, or S-configuration at the stereogenic center is marked with an *; which process hydrogenates an enamide compound of formula III: in an organic solvent in the presence of a transition metal precursor complexed to a chiral phosphine ligand catalyst; wherein Ar is phenyl which is unsubstituted or substituted; Z is OR1, SR1 and NR1R2; and P is R3, OR3, and NR3R4; R1 and R2 are selected from H, C1-8 alkyl, C5-12 cycloalkyl, aryl and aryl-C1-2-alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a C4-7-member heterocyclic ring system optionally fused with a 5- to 6-member carbocyclic or heterocyclic ring system; and R3 and R4 are selected from H, C1-8 alkyl, aryl, C5-12 cycloalkyl and aryl-C1-2-alkyl; or R3 and R4 together with the nitrogen atom to which they are attached form a C4-7-member heterocyclic ring system.